A research group of the multiple sclerosis (MS) Center Amsterdam, led by assistant professor Gijs Kooij, studied the clinical potential of pro-resolving lipid mediator Lipoxin A4 in MS and model systems. They discovered that this lipid mediator not only ameliorated neuro-inflammation, but also that it dampened pro-inflammatory T cell responses in MS patient-derived cells. These results are now published in Cell Reports.